Mega-PBM Merger: Boon or Bane? A Closer Look at the Potential Impact

Strategic Insights -

The proposed merger between Express Scripts (Nasdaq: ESRX) and Medco Health Solutions (NYSE: MHS) has sparked intense debate in the US healthcare industry, with opinions divided on whether it would expand service offerings and reduce costs or have an anti-competitive impact, leading to higher prices and inferior service. The third major player in this niche, CVS Caremark (NYSE: CVS), is closely watching the situation as it considers its own market position.

Key Takeaways:

  • The merger between Express Scripts and Medco Health Solutions could lead to significant cost savings for consumers, labor unions, employers, health plans, and government programs, with estimates suggesting potential savings of 30% in total drug spending relative to unmanaged purchasing.
  • PBMs play a vital role in controlling prescription drug costs and improving chronic care management, with empirical evidence demonstrating their ability to deliver cost savings and improve health outcomes.
  • The proposed merger would result in a dominant player in the PBM space, raising concerns about the potential for anti-competitive practices and higher prices for consumers.
  • The FTC has issued a 'second request' to both Medco and Express Scripts, seeking additional information regarding the pending deal and supported by the American Antitrust Institute (AAI).
  • Patient non-adherence is estimated to cost up to $290 billion per year, representing about 13% of all health expenditures.
  • PBMs are playing a significant role in the clinical management of chronic diseases, where patients account for approximately 96% of drug spending and 75% of total healthcare expenditures in the US.
  • Jonathan Orszag estimates that the combined entity would accelerate annual savings for clients to a large extent, with potential savings of $87 billion per year.

Statistics:

  • Total drug spending could be reduced by 30% through PBM penetration (CBO estimate)
  • Potential savings of $51 billion per year through individual PBMs (Jonathan Orszag estimate)
  • Combined entity expected to save $87 billion per year (Jonathan Orszag estimate)
  • Patient non-adherence estimated to cost up to $290 billion per year
  • PBMs control about 96% of drug spending and 75% of total healthcare expenditures in the US (clinical management of chronic diseases)

Sources:

  • "Mega-PBM Merger: Boon or Bane?" by Zacks.com (Dec. 28)
  • Congressional Budget Office (CBO) estimate (no date mentioned)
  • Jonathan Orszag study (no date mentioned)
  • American Antitrust Institute (AAI) statement (no date mentioned)
  • Zacks Equity Research (http://at.zacks.com/?id=5513)